Dopamine is essential for movement. Giving more has not restored movement after stroke.

October 29, 2026 PubMed publication record · Cochrane systematic review of 12 randomized trials; mixed certainty · Primary source

Stroke rehabilitation is one of medicine’s most human enterprises: retraining movement through repetition, attention, feedback and the brain’s capacity to adapt. Dopamine has been proposed as a pharmacologic way to amplify that plasticity. The latest Cochrane review examined whether levodopa or dopamine agonists actually improved motor recovery when rehabilitation was otherwise comparable.

Twelve randomized studies included 1,860 people. Six trials with extractable continuous motor outcomes (1,258 participants) produced a pooled estimate too heterogeneous and imprecise to support benefit (SMD 1.42, 95% CI −0.20 to 3.05; I²=99%). Crucially, a sensitivity analysis of two trials at low risk of bias representing 1,025 participants found an effect essentially at zero (SMD 0.02, 95% CI −0.10 to 0.14). The pooled serious-adverse-event ratio was 1.03 (95% CI 0.83–1.27). Overall certainty ranged from low to very low.

The finding does not mean dopaminergic signaling is irrelevant to learning; it means these drug strategies have not established better patient movement. Future trials could still test a different subgroup, dose or pairing with rehabilitation, but the intervention has to improve function. This belongs in both The Ascent and the game: training, adaptation and motor control are complex systems, not a single neurotransmitter switch.

Clinical reading: Do not routinely add levodopa solely to enhance poststroke motor recovery on the present evidence.